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Pegvisomant for the Treatment of Gsp-Mediated Growth Hormone Excess in
Patients with McCune-Albright Syndrome
Abstract
Context: GH excess affects approximately 20% of the patients with McCune-Albright syndrome (MAS).
MAS is caused by sporadic, postzygotic, activating mutations in the GNAS gene, which codes for the
cAMP-regulating protein, Gsα (gsp oncogene). These same mutations are found in approximately one
third of the sporadic cases of acromegaly.
Objective: We examined efficacy of the GH receptor antagonist, pegvisomant, in controlling gsp
oncogene-mediated GH excess and skeletal disease (fibrous dysplasia of bone) associated with MAS.
Setting and Patients: Five MAS patients with GH excess were treated with 20 mg/d sc injection of
pegvisomant for 12 wk in a randomized, double-blind, placebo-controlled crossover study at the National
Institutes of Health.
Main Outcome Measures: The primary measure of efficacy was normalization of IGF-I. Secondary
outcome measures were reduction in serum IGF binding protein-3 (IGFBP-3), improvement of fatigue and
sweating, and reduction in markers of bone metabolism and bone pain.
Results: Combined mean changes in serum IGF-I at 6 and 12 wk were −236.4 ng/ml (53%, P < 0.005) and
−329.8 ng/ml (62%, P < 0.001), respectively. IGFBP-3 decreased by 0.8 mg/liter (24%, P < 0.01) and 2.9
mg/liter (37%, P < 0.005), respectively. There were no significant changes in signs and symptoms of
acromegaly or markers of bone metabolism and bone pain, nor was there a significant change in pituitary
size. Retrospective comparison of the degree of control achieved with pegvisomant vs. other medications
(long-acting octreotide ± dopamine agonist) in the same group showed that the two regimens were
similarly effective.
Conclusions: Pegvisomant effectively reduced IGF-I and IGFBP-3 levels in gsp-mediated GH excess but
had no effect on fibrous dysplasia.
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Pegvisomant for the Treatment of gsp-Mediated Growth
Hormone Excess in Patients with McCune-Albright
Syndrome
Sunday O. Akintoye, Marilyn H. Kelly, Beth Brillante, Natasha Cherman, Sarah Turner,
John A. Butman, Pamela G. Robey, and Michael T. Collins
Craniofacial and Skeletal Diseases Branch (S.O.A., M.H.K., B.B., N.C., P.G.R., M.T.C., S.T.) and Diagnostic Radiology
Department (J.A.B.), Clinical Center, National Institutes of Health, Department of Health and Human Services, Bethesda,
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Context: GH excess affects approximately 20% of the patients with
McCune-Albright syndrome (MAS). MAS is caused by sporadic,
postzygotic, activating mutations in the GNAS gene, which codes for
the cAMP-regulating protein, Gs␣ (gsp oncogene). These same mutations are found in approximately one third of the sporadic cases of
acromegaly.
Objective: We examined efficacy of the GH receptor antagonist,
pegvisomant, in controlling gsp oncogene-mediated GH excess and
skeletal disease (fibrous dysplasia of bone) associated with MAS.
Setting and Patients: Five MAS patients with GH excess were
treated with 20 mg/d sc injection of pegvisomant for 12 wk in a
randomized, double-blind, placebo-controlled crossover study at the
National Institutes of Health.
Main Outcome Measures: The primary measure of efficacy was
normalization of IGF-I. Secondary outcome measures were reduction

M

CCUNE-ALBRIGHT SYNDROME (MAS) is classically defined clinically by the triad of polyostotic
fibrous dysplasia of bone (FD), café-au-lait skin pigmentation, and hyperfunctioning endocrinopathies, such as precocious puberty (PP), GH excess (acromegaly), hyperthyroidism, hypercortisolism, and renal phosphate wasting
associated with rickets/osteomalacia (1–3). The underlying
molecular etiology of MAS is a postzygotic mutation of the
GNAS gene (R201H,C,S,G) that encodes for the ␣-subunit of
the stimulatory heterotrimeric G protein complex, Gs␣ (4, 5).
These result in a constitutive activation of the adenylyl cyclase enzyme signal transduction pathway and dysregulated
production of cAMP (6). The constellation of phenotypic
presentations seen in MAS is an example of mosaicism and
results from the involvement of cells in the affected tissues
that harbor the gsp mutation and respond to the hormonesensitive adenylyl cyclase signal transduction pathway.
About 20% of MAS patients have GH excess (7, 8). How-

First Published Online May 23, 2006
Abbreviations: FD, Fibrous dysplasia of bone; IGFBP, IGF binding
protein; LAR, long-acting sandostatin; MAS, McCune-Albright syndrome; MRI, magnetic resonance imaging; OGTT, oral glucose tolerance
test; PP, precocious puberty.
JCEM is published monthly by The Endocrine Society (http://www.
endo-society.org), the foremost professional society serving the endocrine community.

in serum IGF binding protein-3 (IGFBP-3), improvement of fatigue
and sweating, and reduction in markers of bone metabolism and bone
pain.
Results: Combined mean changes in serum IGF-I at 6 and 12 wk were
⫺236.4 ng/ml (53%, P ⬍ 0.005) and ⫺329.8 ng/ml (62%, P ⬍ 0.001),
respectively. IGFBP-3 decreased by 0.8 mg/liter (24%, P ⬍ 0.01) and
2.9 mg/liter (37%, P ⬍ 0.005), respectively. There were no significant
changes in signs and symptoms of acromegaly or markers of bone
metabolism and bone pain, nor was there a significant change in
pituitary size. Retrospective comparison of the degree of control
achieved with pegvisomant vs. other medications (long-acting octreotide ⫾ dopamine agonist) in the same group showed that the two
regimens were similarly effective.
Conclusions: Pegvisomant effectively reduced IGF-I and IGFBP-3
levels in gsp-mediated GH excess but had no effect on fibrous
dysplasia. (J Clin Endocrinol Metab 91: 2960 –2966, 2006)

ever, the diagnosis of GH excess in MAS is sometimes difficult. In children with MAS, rapid linear growth as a sign of
GH excess is often ascribed to PP, which is seen in the
majority of patients with MAS. And whereas patients with
PP would be expected to have diminished final height, those
with concomitant GH excess often attain (or exceed) the
predicted midparental height. Therefore, normal stature in a
person with MAS and PP can be a sign of GH excess (8).
Additionally, the diagnosis is often delayed or missed because the characteristic coarsening of the face, frontal bossing, and prognathism evolve insidiously and may be obscured or attributed to the progression of the fibrous
dysplastic bone lesions in the skull, which themselves can
lead to some degree of dysmorphism in the absence of GH
excess. It is important to diagnose and treat GH excess in
MAS because GH excess is a risk factor for loss of vision and
hearing (due to GH-fueled expansion of FD) as well as dramatic macrocephaly and dysmorphism (8, 9).
The same mutations in Gs␣ that are found in MAS are
present in the adenomatous tissue of approximately one
third of the patients with sporadic acromegaly, suggesting
that these mutations may also be the molecular etiology in
those sporadic cases of sporadic acromegaly. GH plays a
central role in skeletal development and maintenance, both
through direct effects and those mediated by IGF-I (10). IGFs
circulate by binding to six different types of IGF binding
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TABLE 1. Demographics and clinical and molecular characterization of the study cohort
Patient 1

Age (yr)
Gender
Weight (kg)
Pituitary adenoma on MRI
Baseline random GH
(NR ⫽ 0 –5.0 ng/ml)
Baseline IGF-I (ng/ml; Z score)
Serum GH at 60 and 120 min after
OGTT (ng/ml)
Fibrous dysplasia
GNAS mutationa
Skeletal disease burden scoreb
Baseline head circumference (cm)
Previous GH excess therapyc
Effective drug therapy
Other endocrinopathies

Patient 2

Patient 3

Patient 4

Patient 5

33
Male
127
Yes
75.6

39
Female
62
No
7.4

17
Male
78
No
5.6

37
Female
76
Yes
23.4

13
Female
52
Yes
17.3

734 (8.2)
101, 60.2

270 (0.6)
6.1, 3.9

460 (1.8)
2.2, 1.2

554 (4.6)
16, 14.3

436 (1.8)
16.3, 14.8

Polyostotic
Arg201Cys
58.3
85
LAR(30) ⫹ DA(2)
None
PP, LT, RPW

Polyostotic
Arg201Cys
17.7
60
LAR(30) ⫹ DA(2)
LAR
n/a

Polyostotic
Arg201Cys
58.2
66
LAR(30) ⫹ DA(2)
LAR
PP, HT, LT, ST

Polyostotic
Arg201Cys
23.7
69
LAR(30) ⫹ DA(8)
LAR
PP

Polyostotic
Arg201His
59.5
59
LAR(30) ⫹ DA(1)
LAR⫹DA
PP, HT, RPW

n/a, Not applicable; HT, hyperthyroidism; LT, Leydig cell tumor of testes; RPW, renal phosphate wasting; ST, Sertoli cell tumor of the testes;
NR, normal range.
a
Substitution of the amino acid cysteine (Cys) or histidine (His) for arginine at position 201 determined from bone specimen.
b
See Ref. 14.
c
(30), 30 mg/month; DA, dopamine agonist; (), dose of cabergline per week.

proteins (IGFBPs), of which IGFBP-3 is the most abundant
(11, 12) and in some cases may be a sensitive marker for GH
excess.
Conventional treatments of GH excess include surgery,
medications, and radiotherapy. However, in patients with
MAS, transphenoidal surgery is often not possible due to
massive thickening of the skull base with FD, and radiation
therapy is avoided because FD is prone to sarcomatous transformation after radiation (13). Therefore, medical therapy is
often the only reasonable choice. Medical options include
short- and long-acting analogs of somatostatin, dopamine
receptor agonists, and more recently the GH receptor antagonist, pegvisomant. Somatostatin analogs and/or dopamine
receptor agonists are not always effective in MAS (8), and it
is unclear whether controlling GH excess affects FD. In addition, there has not been a report on the efficacy of a medical
treatment of GH excess in a population of patients whose
disease is of a single molecular etiology. Therefore, we tested
the efficacy of pegvisomant in a population of patients with

FIG. 1. Correlation between baseline serum
IGF-I and head circumference. There was a significant association between head circumference
(expressed as percent of the age- and gender-specific upper limit of normal) and baseline serum
IGF-I. This is a reflection of macrocephaly, a GH
excess-related morbidity in MAS.

MAS in normalizing serum IGF-I and, secondarily, its ability
to decrease serum IGFBP-3, signs and symptoms of GH excess, bone pain and markers of bone metabolism in the FD
associated with MAS.
Patients and Methods
Design
The study was a double-blinded, placebo-controlled, crossover study.
Before enrollment, there was a 12-wk washout period during which all
medications for the treatment of GH excess were discontinued. Subjects
were randomized to either drug or placebo for 12 wk, after which there
was a 6-wk washout period. Subjects were then crossed over to placebo
or drug for the final 12 wk. The primary measure of pegvisomant efficacy
was the age- and gender-specific normalization of serum IGF-I. Secondary measures of efficacy were normalization of serum level of
IGFBP-3, improvement in signs and symptoms of GH excess (sweating
and fatigue), decrease in serum and urine markers of bone metabolism,
and a decrease in bone pain. Serum and urine samples were collected
at baseline and wk 6, 12, 18, 24, 30, and 36. Liver function tests, hemogram, and electrocardiogram were performed to monitor for adverse
effects. Change in pituitary size was assessed as a measure of drug safety

⬍0.005

⬍0.01
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⫺28
⫺32
⫺32
⫺49
% change

a

5.6
2.7
4.3
1.9
3.3
2.5
5.1
Week 12

Relative to placebo.
b
Normal range ⫽ 1.9 –3.6; in patients 3 and 5, normal range of IGF-I and IGFBP-3 was adjusted for bone age.

⫺42

2.1
4.0
3.8

⫺0.8
⫺24%
⫺2.0
⫺37%
3.6
2.1
3.9
4.3
5.3
5.0
4.3
5.8
4.0
3.2
4.1
3.8
2.8
1.9
3.4
3.5

⬍0.005
⬍0.001
⫺263 (⫺53)
⫺329 (⫺63)
421 (0.5)
105 (⫺2.7)
98 (⫺2.8)
⫺75
176 – 442
436 (0.2)
488 (0.6)
450 (0.3)

554 (4.6)
797 (8.1)
838 (8.6)
374 (2.1)
872 (9.1)
303 (1.1)
⫺65
106 –368
460 (1.1)
215 (⫺2.2)
191 (⫺2.5)
⫺58
281–510
483 (1.4)
424 (0.6)
494 (1.6)

270 (0.6)
107 (⫺1.6)
90 (⫺1.9)
⫺67
106 –368
269 (0.6)
293 (1.0)
301 (1.1)

IGF-I (ng/ml; Z-score)
Baseline
734 (8.2)
796 (9.2)
Week 6
687 (7.4)
626 (6.4)
Week 12
768 (8.7)
413 (3.0)
% change
⫺48
Normal range
132–333
b
IGFBP-3 (mg/liter)
Baseline
4.4
4.9
Week 6
3.9
3.8

P valuea
Mean change
(%)
Drug

Patient 5

Placebo
Drug

Patient 4

Placebo
Drug

Patient 3

Placebo
Drug

Patient 2

Placebo
Drug

Patient 1

Placebo

Change from baseline
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FIG. 2. Percent change of serum IGF-I during the course of the study.
The change in the serum IGF-I in comparison with the baseline (study
entry) value during the pegvisomant treatment (filled squares) and
placebo (open circles) phases are shown. During the pegvisomant
phase, the serum IGF-I decreased an average of 63% from baseline.
Patient 4 experienced a 57% increase in serum IGF-I during the
course of the placebo phase of the study.
with magnetic resonance imaging (MRI) scanning at baseline and 1 yr.
Pegvisomant was kindly provided by Pfizer Inc. (New York, NY; Pharmacia at the initiation of the study) as single-use, 20-mg strength lyophilized powder that was reconstituted with 1 ml saline for injection.
Each vial of pegvisomant or placebo also contained 1.36 mg glycine, 36
mg mannitol, 1.04 mg sodium phosphate, dibasic (anhydrous), and 0.36
mg monobasic sodium phosphate. Both pegvisomant and placebo appeared similar in color after reconstitution. When a patient was on
pegvisomant, the first dose was a loading dose of 40 mg followed by
daily sc administration of 20 mg. The study was approved by the Institutional Review Board of the National Institute of Dental and Craniofacial Research, National Institutes of Health.

Patients
Five patients were studied. There were 10 patients (adults and children) in the NIH cohort who were eligible for enrollment. Five declined
enrollment for personal reasons, which included unwillingness to discontinue medical treatment for the washout period. MAS was diagnosed
by a combination of clinical history; characteristic radiographic and
histological features of FD; endocrine testing; and, when necessary,
analysis of GNAS gene mutation. The age range was 13–39 yr, with a
mean of 28 yr (Table 1). GH excess was diagnosed by clinical signs and
symptoms of GH excess, elevated serum GH and IGF-I levels, but the
key criterion for the diagnosis was a serum GH that did not suppress
less than 1 ng/ml at 60 min on a standard oral glucose tolerance test
(OGTT). Patient 2 (Table 1) had a normal IGF-I at baseline but a GH that
did not suppress on OGTT and complications known to be associated
with GH excess; one optic nerve decompression, and six facial/sinus
operations. None of the patients had had pituitary surgery, due to the
fact that either a pituitary adenoma was not visualized or they were
considered inoperable due to the thickness of the skull base. None of the
patients had prior radiotherapy because radiotherapy is a risk factor for
transformation of FD to a malignancy (13) and is used only as a last
resort. All patients had significant skeletal disease burden of FD (14).
Four of the five patients had a history of other endocrine disorders, but
only three had a demonstrable pituitary adenoma by MRI (Table 1).

Methods
Serum IGF-I and IGFBP-3 were measured by RIA (Esoterix Inc.,
Austin TX). Serum lGF-I Z-scores were computed using reference ranges
specific for the IGF-I assay. Serum GH was measured using a commercial
immunochemiluminometric assay (Mayo Medical Laboratories, Rochester, MN) that was modified to avoid cross-reactivity with pegvisomant. Antipegvisomant antibodies were measured by MDS Pharma
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FIG. 3. Sweating, fatigue, and pain scores. Patients kept
weekly logs and recorded sweating and fatigue scores (A)
and pain scores (B). The mean score ⫾ 1 SD for each patient
on drug (filled bars) and placebo (open bars) are shown. A
standardized, validated tool for the assessment of sweating
and fatigue was used (see Refs. 15 and 16), and the Brief
Pain Inventory was used to assess pain. As a group, there
were no differences in sweating, fatigue, or pain, but two
patients had significantly more pain on drug than placebo.

Services (Montreal, Canada). Patients kept a weekly diary to record
subjective impressions of fatigue and sweating using a visual analog
scale ranging from 0 (none) to 10 (worst) (15, 16). Physical examination
was performed at baseline and wk 12, 18, 30, and 36. Patients were
followed up for at least 12 months after the end of the drug and placebo
period.
Secondary skeletal effects of pegvisomant on FD were assessed by
measuring markers of bone metabolism and bone pain. Bone pain was
measured using a validated, subjective self-assessment tool developed
by the American Pain Society, the Modified Brief Pain Inventory (17).
Bone metabolism markers (serum alkaline phosphatase, bone-specific
alkaline phosphatase, osteocalcin, urine N-telopeptides of collagen, pyridinoline, and deoxypyridinoline cross-links) were measured by standard commercially available assays (Mayo Medical Laboratories).
Pituitary volume was assessed by T1-weighted noncontrast and postcontrast MRI of the brain performed at baseline and 12 months after
enrollment. From sagittal and coronal sequences, anterior-posterior,
superior-inferior, and medial-lateral measurements were recorded at the
maximum dimension to estimate pituitary gland volume.

Statistical analysis
Pegvisomant and placebo primary efficacy data were accessed as
percentage change from baseline and compared using Fisher’s exact test
or the 2 test for the comparison of proportions. Continuous measures
were compared using the two sample t test. Measurements of head

circumference were compared with age and gender-matched controls
(18), Z-scores were calculated using assay-specific age and gendermatched reference values (8), and Pearson’s linear regression was used
to evaluate correlations and degree of significance. Statistical analyses
were two sided, and P ⬍ 0.05 was regarded statistically significant. All
analyses were performed with JMP Windows NT 5.1 statistical package
(SAS Institute, Cary, NC).

Role of funding source
Pfizer Inc. (Pharmacia), manufacturer of pegvisomant, limited its role
to supply of drug, placebo, and funds for patient travel and certain
assays. Study design, coordination, patient care and testing, data analysis, and manuscript preparation were the sole responsibilities of the
investigators.

Results

All patients had signs and symptoms of GH excess including macrocephaly, the degree of which correlated with
baseline IGF-I levels (R ⫽ 0.91, P ⬍ 0.05, Fig. 1). The mean
baseline IGF-I for the group was 491 ng/ml.
A daily dose of 20 mg pegvisomant for 12 wk successfully
reduced serum IGF-I in all patients at 6 wk [combined mean

TABLE 3. Serum GH and pegvisomant levels, and anti-pegvisomant antibodies
Placebo

Mean change in GH compared with baseline (%)
P value (differences between placebo and pegvisomant)
Mean pegvisomant level (ng/ml)
Anti-pegvisomant antibodies

Pegvisomant

Week 6

Week 12

Week 6

Week 12

⫺8.6

0.1

0
Negative

0
Negative

⫺31.9
⬍0.5
23,774
Negative

⫺4.9
⬍0.7
24,211
Negative
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TABLE 4. Markers of bone metabolism
Placebo/drug (% change)
Patient 1

Alkaline phosphatase (U/liter)
(37–116)
Osteocalcin (g/liter) (2–15)
N-telopeptides (pmol/mol Cr.)
(0 – 64)
Pyridinoline crosslinks (nmol/
mmol Cr.) (18 – 40)
Deoxypyridinoline crosslinks
(mol/mol Cr.) (5–14)

474/366 (⫺22)
107/118 (10)
1049/865 (⫺17)

Patient 2

483/539 (11)
22/36 (63)
1402/1186 (⫺15)

Patient 3

Patient 4

Patient 5

Mean
% changea

1224/970 (⫺20)

871/833 (⫺4)

715/515 (⫺30)

⫺13

117/109 (⫺6)
636/609 (⫺4)

37/35 (⫺5)
668/423 (⫺37)

72/40 (⫺44)
1900/1053 (⫺44)

4
⫺23

1008/890 (⫺12)

198/203 (3)

636/609 (⫺4)

348/379 (9)

n/a

⫺1

228/200 (⫺12)

35/36 (⫺3)

223/208 (⫺7)

89/85 (⫺4)

n/a

7

Normal range is in parentheses in first column. n/a, Not available.
No mean changes from baseline were statistically significant.

a

difference ⫺263.4 ng/ml (⫺53%; P ⬍ 0.005)] and 12 wk
[combined mean difference of ⫺329.8ng/ml (⫺63%; P ⬍
0.001, Table 2)]. The differences in serum IGF-I between
baseline or placebo and drug treatment for each patient,
shown as percent changes from baseline, are depicted in Fig.
2. The decrease in IGFBP-3 at 6 wk was significant (combined
mean difference 0.8 mg/liter (24%; P ⬍ 0.01), and 12 wk
[combined mean difference ⫺2.0 mg/liter (37%; P ⬍ 0.001,
Table 2)], suggesting that serum IGF-I may be a better measure of pegvisomant efficacy. There was no significant difference in the degree of the acromegalic symptoms of fatigue
and sweating between the drug and placebo phases (Fig. 3),
nor was there a correlation between the severity of these
symptoms and the degree of IGF-I elevation (data not
shown). Average weekly bone pain score was significantly
higher in two patients during pegvisomant treatment, but as
a group there was no overall effect on pain (Fig. 3).
There was no change in random serum GH at 6 or 12 wk,
antibodies to pegvisomant were undetectable throughout
the study, and serum pegvisomant levels confirmed compliance with study drug use (Table 3).
The levels of the markers of bone metabolism were quite
high, but there was no significant effect of treatment on either
markers of bone formation (alkaline phosphatase and osteocalcin) or resorption (N-telopeptide, pyridinoline, and deoxypyridinoline cross-links; Table 4).
One patient had an increase in pituitary volume over a
12-month period, but as a group, there was no change in
pituitary volume (Fig. 4). All the patients completed the
study with no adverse events.
The efficacy of pegvisomant on lowering serum IGF-I was
compared with the efficacy of the regimen patients were on
before the study. Before the study, all patients were treated
with long-acting sandostatin (LAR) ⫾ cabergoline. The mean
percent decreases in IGF-I by the pretrial regimen and the
pegvisomant were 52 and 63%, respectively (Table 5). One
patient who had not been controlled by LAR ⫹ cabergoline
was controlled by pegvisomant alone.

Successful medical treatment in this group is especially important because these patients are usually not good candidates for surgery due to massive thickening of the skull base
with FD, and they are not good candidates for radiation
because FD can undergo sarcomatous transformation with
radiation treatment. The urgency for successful medical
treatment is intensified by the fact that GH excess in FD is an
independent risk factor for the development of disfiguring
macrocephaly as well as vision and hearing loss, presumably
due to GH-stimulated expansion of FD lesions.
We show here that pegvisomant, a GH receptor antagonist, is an effective treatment for GH excess in patients with
MAS. It significantly lowered both serum IGF-I and IGFBP-3
in all patients and normalized these values in all but one
patient. Whereas this was not a head-to-head trial comparing
the efficacy of pegvisomant with other therapies, the efficacy
of pegvisomant was retrospectively compared with that of
LAR ⫾ cabergoline. As a group there was no difference in the
degree of control, but one patient (patient 4) whose IGF-I had
not been normalized by a combination of LAR ⫹ cabergoline
was controlled on pegvisomant alone (Table 5). The single
patient whose IGF-I was not normalized by pegvisomant
(patient 1) went on to be treated with a combination of both
LAR and pegvisomant, and even with this combination, the
IGF-I did not normalize. This is different from what was seen

Discussion

The medical treatment of a group of patients with GH
excess in the context of MAS offers the unique opportunity
to study the effects of a drug in a group of acromegalic
patients whose disease is of a single molecular etiology, gsp.

FIG. 4. Pituitary volume. The pituitary volume was assessed by MRI
at baseline and 12 months later. As a group there was no change in
pituitary volume.
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TABLE 5. Comparison of response to pretrial medication (Rx) and pegvisomant
Patient no.

Pretrial medical regimen
% decrease IGF-I on pretrial Rx
% decrease IGF-I on pegvisomant
Normalized IGF-I on pretrial Rx
Normalized IGF-I on pegvisomant
a
b
c

1

2

3

4

5

LARa ⫹ CABb
31
48
No
No

LAR
62
67
Yes
Yes

LAR
62
58
Yes
Yes

LAR ⫹ CAB
58
65
No
Yes

LAR ⫹ CAB
47
75
Yes
Yes

Mean
% change
in IGF-I

⫺52
⫺63c

LAR, Long-acting somatostatin agonist sandostatin LAR.
CAB, Dopamine agonist cabergoline.
P ⫽ 0.13 for difference between pretrial medication (Rx) and pegvisomant.

in an earlier study that reported additive effects of pegvisomant in combination with long-acting somatostatin analogs (19). It should be noted that this patient’s weight was 127
kg, and his baseline GH and IGF-I were very high, 75.6 and
734 ng/ml, respectively. Given his large body mass and very
high baseline GH and IGF-I values, it is possible that the fixed
dose (by protocol) of pegvisomant may not have been sufficient to call this a pegvisomant failure. Interestingly, in this
group of patients, there was not a significant increase in the
serum GH while on pegvisomant (Table 3), as had been
reported in other studies (20, 21). The reason for this difference is not known but could reflect that feedback inhibition
is lost at baseline in gsp-mediated acromegaly and that when
IGF-I is lowered by pegvisomant, there is no further loss of
feedback inhibition and thus no increase in serum GH.
Whereas pegvisomant seems to be marginally better than the
pretrial medical regimen, there was no significant difference
in response to therapy in patients with gsp-mediated GH
excess.
Although pegvisomant lowered serum IGF-I and IGFBP-3,
it was disappointing that the drug had no effect on the GH
excess-related symptoms of fatigue and sweating. It is possible that this lack of effect was due to either the relatively
short duration of treatment or the fact that the dose of pegvisomant was not titrated to relief of symptoms. It was reassuring that attenuation of the inhibitory feedback effect of
high IGF-I caused no change in pituitary volume as a group,
at least during the period under study. It is possible that
progression in tumor size that was observed in one patient
may be the result of disease progression. This point may be
a reflection of the relatively short study length; therefore, as
in other medical treatments of GH excess, tumor size should
be monitored in patients on chronic pegvisomant treatment.
One of the expectations of this study was that the blockade
of GH receptors or the secondary lowering of serum IGF-I
would improve FD symptoms as assessed by a decrease in
bone pain and/or a decrease in markers of bone metabolism.
Whereas there was a trend toward lower levels of markers
of bone metabolism, this was not statistically significant,
perhaps attributable to the small number of patients studied
(Table 4). This is somewhat surprising, given the fact that
previous studies have shown that treatment of acromegalic
patients, in whom markers of bone turnover were high at
baseline, with pegvisomant resulted in reductions of markers
of bone turnover (22–24). In addition, there was no improvement in bone pain, and in fact two patients experienced a
significant increase in bone pain. It is not clear whether this
was related to drug effect or disease progression.

Given the potential for tumor shrinkage by LAR and the
established long-term safety of long-acting somatostatin analogs, our recommendation for the initial treatment of GH
excess in MAS is a trial of LAR. If this response is inadequate,
high-dose dopamine agonist or pegvisomant may be added.
If medical therapy is inadequate, and access to the pituitary
is not prohibited by bone overgrowth, surgery may be an
option. However, even in cases wherein it appears that a
single, discreet adenoma is the cause of excess GH, the gland
is often diffusely involved with areas of somatotroph hyperplasia, and the only option for surgical cure is total hyphophysectomy. The remaining option is radiation, which
should also be approached with caution because FD, which
always encases the pituitary in MAS, is prone to sarcomatous
transformation after treatment doses of radiation (13). This
risk may be minimized with technologies using focused
beam irradiation.
In summary, pegvisomant effectively controlled GH excess in patients with MAS and was at least as effective as LAR
in normalizing serum IGF-I.
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